1822 de Sabadell, Sabadell) (8); Batlle i Nadal, J. (H. Santa Tecla, Tarragona) (8); Calles, C., Nun˜ ez V. (H. Son Dureta, Palma de Mallorca) (8); Mallada Frech´ın, J. (H. Virgen de la Salud de Elda, Elda) (8); Eguia, P. (H. Doctor Jose´ Molina Orosa, Lanzarote) (7); Meca-Lallana, V. (H. Uni- versitario de La Princesa, Madrid) (7); Reyes Ya´nez, M.P. (H. Universitario Insular de Gran Canarias, Las Palmas de Gran Canaria) (7); Ayuso Peralta, L., Rubio Pe´rez, L. (H. Universitario Pr´ıncipe de Asturias, Alcala´ de Henares) (7); Casado, J.L., Gonza´lez Oria, C., Ucle´s Sa´nchez, A. (H. Universitario Virgen del Roc´ıo, Sevilla) (7); Caminero, A. (Complejo Hospitalario Ntra. Sra. de Sonsoles, A´ vila) (6); Cano, A. (H. de Mataro´ , Mataro´ ) (6); Berenguer, L., Pe´rez Carmona, N. (H. Marina Baixa, Villajoyosa) (6); Pato Pato, A. (H. POVISA, Vigo) (6); Guijarro-Castro, C. (H. Uni- versitario 12 De Octubre, Madrid) (6); Miralles Mart´ınez, A. (H. Universitario Infanta Sof´ıa, San Sebastia´n de los Reyes) (6); Rodr´ıguez Garc´ıa, E. (H. Universitario Severo Ochoa, Legane´s) (6); Losada Lo´ pez, M. (Fundacio´ n Jime´nez D´ıaz, Madrid) (5); Aguirre Sa´nchez, J.J. (H. Infanta Cristina, Badajoz) (5); Sua´rez Ferna´ndez, G. (H. Ntra. Sra. del Prado, Talavera de la Reina) (5); Carod- Artal, F.J., Lo´ pez Mart´ınez, A. (H. Virgen de La Luz, Cuenca) (5); Garc´ıa Montero, M.R. (H. Virgen de La Sa- lud, Toledo) (5); A´ lvarez de Arcaya, A. (H. de Txagorritxu, Vitoria) (4); Go´ mez Gutie´rrez, M. (H. San Pedro de Al- ca´ntara, Ca´ceres) (4); Dom´ınguez-Mora´n, J.A., Peiro´ Vilaplana, C. (H. Universitario De La Ribera, Alzira) (4); Garc´ıa-Monco´ , C., Mediavillam J., Sa´nchez Menoyo, J.L. (H. de Galdakao-Usansolo, Galdakao) (3); Landete Pasc- ual, L. (H. Dr. Peset, Valencia) (3); Lacruz Ballester, L. (H. Francesc de Borja, Gand´ıa) (3); Ballabriga Planas, J. (H. Son Lla´tzer, Palma de Mallorca) (3); Aladro, Y. (H. Uni- versitario de Getafe, Getafe) (3); Castillo, L., Borrega, L. (H. Universitario Fundacio´ n Alcorco´ n, Alcorco´ n) (3); Perla Muedra, C., Valero Merino, C. (H. Arnau de Villanova, Valencia) (2); Qu´ılez Mart´ınez, A. (H. Arnau de Villanova, Lleida) (2); Sistiaga, C. (H. Bidasoa y Policl´ınica Gip- uzkoa, Hondarribia) (2); Mu n˜oz Ma´laga, A. (H. de Jerez, Jerez de la Frontera) (2); Navarre´-Gimeno, A. (H. de Sagunto, Valencia) (2); Gonza´lez Platas, M. (H. Univer- sitario Canarias, Santa Cruz de Tenerife) (2); Carmona, O. (Fundacio´ Salut Emporda´, Figueras) (1); Mendoza Rodr´ı- guez, A. (H. General de Segovia, Segovia) (1); Taleti, E. L. (H. General Mateu Orﬁla, Mao´ ) (1); Romero Lo´ pez, J. (H. Meixoeiro, Vigo) (1); Jarauta Salvador, F. (H. Reina Sof´ıa, Tudela) (1). References 123 1. Le´ger OJ, Yednock TA, Tanner L, Horner HC, Hines DK, Keen S et al (1997) Humanization of a mouse antibody against human J Neurol (2012) 259:1814–1823 alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 8:3–16 2. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA (1993) Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 177:57–68 3. Stu¨ ve O, Bennett JL (2007) Pharmacological properties, toxi- cology and scientiﬁc rationale for the use of natalizumab (Ty- sabri) in inﬂammatory diseases. CNS Drug Rev 13:79–95 4. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA et al (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15–23 5. O’Connor P, Miller D, Riester K, Yang M, Panzara M, Dalton C et al (2005) Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. Mult Scler 11:568–572 6. Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899–910 7. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Eng J Med 354:911–923 8. Putzki N, Yaldizli O, Ma¨urer M, Cursiefen S, Kuckert S, Klawe C et al (2010) Efﬁcacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol 17:31–37 9. Oturai AB, Koch-Henriksen N, Petersen T, Jensen PE, Sellebjerg F, Sorensen PS (2009) Efﬁcacy of natalizumab in multiple scle- rosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 16:420–423 10. Sangalli F, Moiola L, Bucello S, Annovazzi P, Rizzo A, Radaelli M et al (2010) Efﬁcacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci 31(Suppl 3):299–302 11. Prosperini L, Borriello G, Fubelli F, Marinelli F, Pozzilli C (2010) Natalizumab treatment in multiple sclerosis: the experi- ence of S. Andrea MS centre in Rome. Neurol Sci 31(Suppl 3):303–307 12. Outteryck O, Ongagna J, Ze´phir H, Fleury MC, Lacour A, Blanc F et al (2010) Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol 257:207–211 13. Mancardi GL, Tedeschi G, Amato MP, D’Alessandro R, Drago F, Milanese C et al (2010) Three years of experience: the Italian registry and safety data update. Neurol Sci 31(Suppl 3):295– 297 14. Putzki N, Yaldizli O, Bu¨hler R, Schwegler G, Curtius D, Tettenborn B et al (2010) Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol 63:101–106 15. Piehl F, Holme´n C, Hillert J (2010) Swedish natalizumab (Tysabri) multiple sclerosis surveillance study. Neurol Sci 31(Suppl 3):289–293 16. Ferna´ndez O, Alvarenga MP, Guerrero M, Leo´n A, Alonso A, Lo´pez-Madrona JC et al (2011) The efﬁcacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study. Mult Scler 17:192–197 17. Horga A, Castillo J, Rio J, Tintore M, Auger C, Sastre-Garriga J et al (2011) An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. Rev Neurol 16(5):321–333 18. Belachew S, Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H et al (2010) Natalizumab (Tysabri ) observational program: associations of baseline disease activity and treatment history with postbaseline relapses in multiple sclerosis patients